A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Phillip Garfin, MD, PhD
Seagen Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope National Medical Center
Duarte, California, United States
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
- University of Chicago
Chicago, Illinois, United States
- University of Kansas Cancer Center
Westwood, Kansas, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Weill Cornell Medical College
New York, New York, United States
- Case Western Reserve University / University Hospitals Case Medical Center
Cleveland, Ohio, United States
- Md Anderson Cancer Center / University of Texas
Houston, Texas, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2015
- Primary completion
- 10 Feb 2017
- Completion
- 14 Sept 2017
- Last update posted
- 9 Jan 2019
- Registered enrollment
- 14
- Registry id
- NCT02614560
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.